Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Colchicine in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial

Journal article

Horby PW. et al, (2021), Lancet Respiratory Medicine, 9, 1419 - 1426

Tocilizumab in COVID-19 therapy: who benefits, and how? - Authors' reply.

Working paper

Horby P. et al, (2021), Lancet, 398

Association Between Administration of IL-6 Antagonists and Mortality Among Patients Hospitalized for COVID-19: A Meta-analysis.

Journal article

WHO Rapid Evidence Appraisal for COVID-19 Therapies (REACT) Working Group None. et al, (2021), JAMA

Making trials part of good clinical care: lessons from the RECOVERY trial.

Journal article

Pessoa-Amorim G. et al, (2021), Future Healthc J, 8, e243 - e250

Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial.

Journal article

RECOVERY Collaborative Group None., (2021), Lancet, 397, 1637 - 1645

Hydroxychloroquine in Hospitalized Patients with Covid-19. Reply.

Journal article

Horby P. et al, (2021), N Engl J Med, 384

Dexamethasone in Hospitalized Patients with Covid-19.

Journal article

RECOVERY Collaborative Group None. et al, (2021), N Engl J Med, 384, 693 - 704

Azithromycin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial.

Journal article

RECOVERY Collaborative Group None., (2021), Lancet, 397, 605 - 612

Azithromycin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial.

Journal article

RECOVERY Collaborative Group None., (2021), Lancet, 397, 605 - 612

Load More